<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799054</url>
  </required_header>
  <id_info>
    <org_study_id>TCTLR-101</org_study_id>
    <secondary_id>transcendIT-101</secondary_id>
    <nct_id>NCT04799054</nct_id>
  </id_info>
  <brief_title>A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma Oncology Division A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally&#xD;
      advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8&#xD;
      Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose&#xD;
      expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist&#xD;
      every cycle. The primary objectives are to evaluate safety and tolerability, and define the&#xD;
      Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist&#xD;
      alone or in combination with pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Toll-like receptors (TLRs) are a class of proteins that play a key role in innate immune cell&#xD;
      recognition of foreign pathogens, stimulating innate and adaptive immune responses. TransCon&#xD;
      TLR7/8 Agonist is designed as a long-acting localized delivery prodrug of resiquimod, a&#xD;
      potent toll-like receptor (TLR) 7/8 agonist, with the potential to prolong high local&#xD;
      concentrations of resiquimod and promote potent anti-tumoral responses while reducing&#xD;
      systemic drug exposure and related adverse events. TransCon TLR7/8 Agonist is expected to&#xD;
      stimulate innate and adaptive immune response in the tumor microenvironment and enhance the&#xD;
      activity of checkpoint inhibitors like pembrolizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Through study completion, expected average of 2 years</time_frame>
    <description>Treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Cycle 1 (each cycle is 21 days) in Part 1 (monotherapy dose escalation) and Cycle 1 (the first cycle is 28 days and 21 days thereafter) in Part 2 (combination therapy dose escalation)</time_frame>
    <description>Determine the maximum tolerated dose by assessing the Incidence of Dose Limiting Toxicities (DLTs), treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation and deaths.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine a recommended phase 2 dose of TransCon TLR7/8 Agonist and combination regimen for further development by evaluating number of patients with treatment-related adverse events as assessed by CTCAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Average of two years</time_frame>
    <description>Response assessed by RECIST v1.1 and itRECIST (response assessment for intratumoral immunotherapy for injected and noninjected lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Average of two years</time_frame>
    <description>Time from first documentation of objective tumor response (CR or PR that is subsequently confirmed) to first documentation of disease progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Expected up to 1 year from first dose</time_frame>
    <description>Time from date of first dose of study treatment to first occurrence of response (CR or PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Average of two years</time_frame>
    <description>Time from date of first dose of study treatment to first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Average of two years</time_frame>
    <description>Time from date of first dose of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - Cmax</measure>
    <time_frame>Average of two years</time_frame>
    <description>Maximum observed plasma concentration of resiquimod, O-desethyl resiquimod (metabolite) and total resiquimod (sum of bound and unbound resiquimod) after IT administration of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - tmax</measure>
    <time_frame>Average of two years</time_frame>
    <description>Time to reach maximum plasma concentration of resiquimod, O-desethyl resiquimod (metabolite) and total resiquimod (sum of bound and unbound resiquimod) after IT administration of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - AUC0-t for first dose only</measure>
    <time_frame>Average of two years</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to last sampling time at which the concentration is at or above the lower limit of quantification for resiquimod, O-desethyl resiquimod (metabolite) and total resiquimod (sum of bound and unbound resiquimod) after IT administration of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - t1/2</measure>
    <time_frame>Average of two years</time_frame>
    <description>Apparent terminal half-life of resiquimod, O-desethyl resiquimod (metabolite) and total resiquimod (sum of bound and unbound resiquimod) after IT administration of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - Ctrough</measure>
    <time_frame>Average of two years</time_frame>
    <description>Plasma concentration immediately before next dosing of resiquimod, O-desethyl resiquimod (metabolite) and total resiquimod (sum of bound and unbound resiquimod) after IT administration of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation: TransCon TLR7/8 Agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TransCon TLR7/8 Agonist</intervention_name>
    <description>TransCon TLR7/8 Agonist will be administered as an IT injection</description>
    <arm_group_label>Part 1 Dose Escalation: TransCon TLR7/8 Agonist</arm_group_label>
    <arm_group_label>Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered IV</description>
    <arm_group_label>Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Participants must have histologically confirmed locally advanced, recurrent or&#xD;
             metastatic solid tumor malignancies that cannot be treated with curative intent&#xD;
             (surgery or radiotherapy).&#xD;
&#xD;
          -  Participants must have progressed on or be intolerant of available standard of care&#xD;
             treatment options or have disease for which there is no standard of care treatment&#xD;
             available.&#xD;
&#xD;
          -  At least 2 lesions of measurable disease.&#xD;
&#xD;
          -  Willingness to undergo biopsies.&#xD;
&#xD;
          -  Demonstrated adequate organ function within 14 days of Cycle 1 Day 1 (C1D1).&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks as determined by the Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.&#xD;
&#xD;
          -  Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4&#xD;
             antibody must have at least 4 weeks from the last dose of antibody and evidence of&#xD;
             disease progression per investigator assessment before enrollment.&#xD;
&#xD;
          -  Participants who have previously received an immune checkpoint inhibitor prior to&#xD;
             enrollment must have any immune related toxicities resolved to â‰¤Grade 1 or baseline&#xD;
             (prior to the checkpoint inhibitor) to be eligible.&#xD;
&#xD;
          -  Female and male participants of childbearing potential who are sexually active must&#xD;
             agree to use highly effective methods of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have been previously treated with a TLR agonist (excluding topical&#xD;
             agents for unrelated disease) are not eligible.&#xD;
&#xD;
          -  Participants who have received systemic interferon alpha within the previous 24 weeks&#xD;
             prior to enrollment are not eligible.&#xD;
&#xD;
          -  Other active malignancies within the last 2 years are excluded.&#xD;
&#xD;
          -  Active autoimmune diseases, regardless of need for immunosuppressive treatment at the&#xD;
             time of screening, with the exception of patients well controlled on physiologic&#xD;
             endocrine replacement.&#xD;
&#xD;
          -  Systemic immunosuppressive treatment with the exception for patients on corticosteroid&#xD;
             taper (for example, for chronic obstructive pulmonary disease exacerbation).&#xD;
             Participants cannot start dosing on study until steroid dose is at or lower than 10 mg&#xD;
             per day prednisone or equivalent.&#xD;
&#xD;
          -  Women who are breastfeeding or have a positive serum pregnancy test during screening&#xD;
             or within 48 hours prior to C1D1 are not eligible.&#xD;
&#xD;
          -  Vaccination with live, attenuated vaccines within 4 weeks of enrollment.&#xD;
&#xD;
          -  Symptomatic central nervous system metastases.&#xD;
&#xD;
          -  Known bleeding disorder that is deemed to place the patient at unacceptable risk for&#xD;
             bleeding complications from intratumoral injections or biopsies.&#xD;
&#xD;
          -  Known hypersensitivity to any component of TransCon TLR7/8 Agonist or pembrolizumab.&#xD;
&#xD;
          -  Any uncontrolled bacterial, fungal, viral, or other infection.&#xD;
&#xD;
          -  Treatment with any other anti-cancer systemic treatment (approved or investigational)&#xD;
             or radiation therapy within 4 weeks of first dosing on study is not allowed.&#xD;
&#xD;
          -  Significant cardiac disease&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction&#xD;
             formula.&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart&#xD;
             failure, clinically significant hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  The use of concomitant medications that prolong the QT/QTc interval within 14 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  Positive for HIV or with active hepatitis B or C infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Nyamuswa</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Rushing</last_name>
    <phone>+1.650.512.9048</phone>
    <email>mrg@ascendispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ascendis Pharma</keyword>
  <keyword>TransCon TLR7/8 Agonist</keyword>
  <keyword>Locally Advanced Solid Tumor</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

